A Phase III, Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicentre Study to Assess Efficacy and Safety of Expanded Allogeneic Adipose-derived Stem Cells (eASCs) for the Treatment of Perianal Fistulising Crohn's Disease Over a Period of 24 Weeks and an Extended Follow-up Period up to 104 Weeks

Trial Profile

A Phase III, Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicentre Study to Assess Efficacy and Safety of Expanded Allogeneic Adipose-derived Stem Cells (eASCs) for the Treatment of Perianal Fistulising Crohn's Disease Over a Period of 24 Weeks and an Extended Follow-up Period up to 104 Weeks

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Darvadstrocel (Primary)
  • Indications Rectal fistula
  • Focus Registrational; Therapeutic Use
  • Acronyms ADMIRE; ADMIRE-CD
  • Sponsors Cellerix; TiGenix
  • Most Recent Events

    • 12 Apr 2018 According to a TiGenix media release, 52 week results were presented at the Digestive Disease Week (DDW) annual meeting (May 2017).
    • 23 Mar 2018 According to a TiGenix media release, European Commission (EC) has approved Alofisel (darvadstrocel) to treat complex perianal fistulas in Crohn's disease in Europe.
    • 15 Jan 2018 According to a TiGenix media release, data were published in a Gastroenterology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top